Treatment of Fabry Disease: Outcome of a Comparative Trial with Agalsidase Alfa or Beta at a Dose of 0.2 mg/kg

• Anouk C. Vedder,

  Affiliations Department of Internal Medicine/Endocrinology and Metabolism, Academic Medical Center, Amsterdam, The Netherlands, Department of Medical Biochemistry, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands

  ⨯
• Gabor E. Linthorst,

  Affiliations Department of Internal Medicine/Endocrinology and Metabolism, Academic Medical Center, Amsterdam, The Netherlands, Department of Medical Biochemistry, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands

  ⨯
• Gunnar Houge,

  Affiliation Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway

  ⨯
• Johannna E.M. Groener,

  Affiliation Department of Medical Biochemistry, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands

  ⨯
• Els E. Ormel,

  Affiliation Department of Internal Medicine/Endocrinology and Metabolism, Academic Medical Center, Amsterdam, The Netherlands

  ⨯
• Berto J. Bouma,

  Affiliation Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands

  ⨯
• Johannes M.F.G. Aerts,

  Affiliation Department of Medical Biochemistry, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands

  ⨯
• Asle Hirth,

  Affiliation Department of Heart Disease, Haukeland University Hospital, Bergen, Norway

  ⨯
• Carla E.M. Hollak

  *To whom correspondence should be addressed. E-mail: c.e.hollak@amc.uva.nl

  Affiliation Department of Internal Medicine/Endocrinology and Metabolism, Academic Medical Center, Amsterdam, The Netherlands

  ⨯